GlassScriptPhysician profile
Bruce A Gibson
NPI 1952307902
$4,391.66
in general payments reported to CMS, 2019-2025
28 companies · $466 in 2025
The $466 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,102 · 2020: $121 · 2021: $318 · 2022: $793 · 2023: $935 · 2024: $656 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,057.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,075.28 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $606.99 | 2019-2024 | Xifaxan |
| Gilead Sciences, INC. | $325.08 | 2019-2024 | |
| Janssen Scientific Affairs, LLC | $318.22 | 2021-2024 | Remicade, Stelara, Tremfya |
| Pfizer INC. | $298.64 | 2019-2024 | |
| Janssen Biotech, INC. | $283.82 | 2021-2024 | Stelara, Tremfya, Simponi |
| Boston Scientific Corporation | $258.01 | 2019-2023 | Exalt Model D |
| Lilly USA, LLC | $215.12 | 2024-2025 | Omvoh |
| Celgene Corporation | $183.16 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $136.87 | 2019-2024 | Entyvio, Gattex |
| Medtronic USA, INC. | $125.44 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $103.27 | 2022 | |
| Csl Behring | $97.13 | 2022 | |
| Shionogi INC | $67.16 | 2019 | |
| Intercept Pharmaceuticals, INC. | $54.04 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $31.89 | 2025 | |
| Celltrion USA INC. | $24.62 | 2025 | Vegzelma |
| Mallinckrodt Hospital Products INC. | $23.25 | 2023 | Terlivaz |
| Ipsen Biopharmaceuticals, INC | $22.33 | 2025 | Iqirvo |
| Ardelyx, INC. | $20.71 | 2024 | Ibsrela |
| Ambu INC. | $19.61 | 2021 | |
| Phathom Pharmaceuticals, INC. | $17.28 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $16.98 | 2023 | |
| Shire North American Group INC | $15.33 | 2019 | |
| Nestle Healthcare Nutrition INC. | $13.69 | 2023 | |
| Amgen INC. | $13.66 | 2025 | |
| Braintree Laboratories, INC. | $13.28 | 2024 | Suflave, Sutab |
| Erbe USA INC | $10.80 | 2025 | Vio Cryo Apc |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.